Complementary studies that explore the flow of palmitate, such as isotope-labeled palmitate tracing, could further shed light on the involvement of SCD1 and FADS2 in palmitate metabolism throughout infection and in EBV-transformed tumors, thereby informing future therapeutic approaches that minimize adverse side effects. This evidence concerns the gene SCD and infection.